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We previously demonstrated that the deletion of the
poly(ADP-ribose)polymerase (Parp)-1 gene in mice
enhances oxidative metabolism, thereby protecting
against diet-induced obesity. However, the thera-
peutic use of PARP inhibitors to enhance mitochon-
drial function remains to be explored. Here, we
show tight negative correlation between Parp-1
expression and energy expenditure in heteroge-
neous mouse populations, indicating that variations
in PARP-1 activity have an impact on metabolic
homeostasis. Notably, these genetic correlations
can be translated into pharmacological applications.
Long-term treatment with PARP inhibitors enhances
fitness in mice by increasing the abundance of mito-
chondrial respiratory complexes and boosting mito-
chondrial respiratory capacity. Furthermore, PARP
inhibitors reverse mitochondrial defects in primary
myotubes of obese humans and attenuate genetic
defects of mitochondrial metabolism in human fibro-
blasts and C. elegans. Overall, our work validates in
worm, mouse, and human models that PARP inhibi-
tion may be used to treat both genetic and acquired
muscle dysfunction linked to defective mitochondrial
function.1034 Cell Metabolism 19, 1034–1041, June 3, 2014 ª2014 Elsevier InINTRODUCTION
Reductions in mitochondrial number and activity are a hallmark
of several inherited mitochondrial diseases, as well as a number
of age-related neurodegenerative and metabolic disorders
(Andreux et al., 2013). The sirtuin enzymes have emerged as crit-
ical regulators of mitochondrial and oxidative metabolism
(Houtkooper et al., 2012). Several studies have shown that
NAD+ levels can be rate limiting for the deacetylase activity of
SIRT1, the best-characterized sirtuin (Canto´ and Auwerx,
2012). Boosting intracellular NAD+ levels has hence become an
attractive approach to activate SIRT1 and mitochondrial meta-
bolism. In line with this, NAD+ availability might even determine
circadian shifts in oxidative capacity (Peek et al., 2013).
One strategy to increase NAD+ levels consists of the inhibition
of alternative NAD+-consuming enzymes, such as poly(ADP-
ribose) polymerase-1 (PARP-1) (Bai and Canto´, 2012), which is
involved in DNA damage detection and repair. Upon activation,
PARP-1 can deplete intracellular NAD+ levels by 80%. Genetic
ablation of Parp-1 increases NAD+ availability and SIRT1 activity
in tissues, such as skeletal muscle and brown adipose tissue (Bai
et al., 2011). As a consequence, mitochondrial oxidative capac-
ity is enhanced in muscle of Parp-1/ mice, protecting them
against high-fat diet (HFD)-induced insulin resistance. Therefore,
PARP inhibition constitutes a plausible strategy to improve
metabolic homeostasis. PARP inhibitors (Paribs) already exist
and are clinically tested in the cancer field (Curtin and Szabo,
2013). The role of PARPs in genome maintenance, however,c.
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Figure 1. Paribs Protect from HFD-Induced Metabolic Complications
Ten-week-old male C57BL/6J mice were challenged with HFD supplemented with either vehicle (DMSO; Veh) or MRL-45696 (50 mg/kg/day) (n = 10/group). (A)
Body weight gain during 18 weeks of HFD. (B) Fat mass was measured using Echo-MRI. (C and D) A comprehensive laboratory animal monitoring system was
used to evaluate VO2 (C) and activity (D) after 7 weeks of HFD. (E) Food intake measured by averaging weekly food consumption during HFD. (F) Liver 8-oxo-dG,
an indicator of DNA damage, (G) muscle lipid peroxidation-derived aldehyde, 4-hydroxy-2-nonenal, and (H) muscle total poly(ADP-ribose) (PAR) contents were
measured in vehicle and MRL-45696-treated mice (n = 7/group). (I and J) Total intracellular (I) and mitochondrial (J) NAD+ levels in gastrocnemius of refed vehicle
and MRL-45696-treated mice (n = 5–10/group). (K) SIRT1, acetylated FOXO1, and total FOXO1 protein levels were assessed in total homogenates from
quadriceps of chow-diet-fedmice. (L) The acetylation status of NDUFA9 immunoprecipates was tested as amarker of SIRT3 activity. Values are shown asmean ±
SEM. Asterisk indicates statistical significant difference versus respective Veh group. *p < 0.05; **p < 0.01; ***p < 0.001. This figure is complemented by Figures
S1 and S2 and Table S1.
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PARP Inhibitors Improve Muscle Functionquestions whether Paribs can be used therapeutically over
longer periods of time to prevent the detrimental metabolic con-
sequences of mitochondrial dysfunction. Here, we demonstrate
that long-term Parib treatment is sustainable and improvesmito-
chondrial function in skeletal muscle, enhancing endurance
performance and protecting against HFD-induced metabolic
complications. We furthermore show that Parp-1 expression is
negatively correlated with energy expenditure in mouse genetic
reference populations. Finally, we demonstrate how acquired
and genetic mitochondrial defects can be improved by Paribs.
Therefore, our work sets the stage for the possible clinical use
of Paribs in situations of defective mitochondrial function.
RESULTS AND DISCUSSION
Characterization of Paribs in C2C12 Myotubes
We initially compared how different Paribs, BSI-201, PJ-34,
ABT-888, AZD-2881, and MRL-45696, could rescue NAD+
decline upon H2O2-induced PARP-1 activation in differentiated
mammalian cell lines, such as C2C12 myotubes. MRL-45696,
a dual PARP-1 and PARP-2 inhibitor derived from niraparib
(Chinnaiyan et al., 2012; Jones et al., 2009), most efficiently
rescued the H2O2-induced NAD
+ decline, with a low nanomolar
IC50 (see Table S1 available online). MRL-45696 reduced the
redox potential in C2C12 myotubes at concentrations as low
as 1–10 nM (Figure S1A) and increasedmitochondrial membrane
potential (MMP) (Figure S1B) and O2 consumption rates (OCRs)Cellat 10 nM (Figure S1C). To certify that the effects of MRL-45696
are derived from PARP inhibition, we also used another Parib,
AZD-2281 (Olaparib). In agreement, nanomolar concentrations
of AZD-2281 decreased redox potential, while increasing MMP
and OCR (Figures S1E–S1G). Notably, MRL-45696 and AZD-
2281 were not toxic at these concentrations, as ATP content
was unaffected (Figures S1D and S1H).
Chronic PARP Inhibition Enhances Energy Expenditure
and SIRT1 Activity
As defects in mitochondrial metabolism are a hallmark for many
diseases, Paribs could in principle also be used for these nonon-
cological indications. However, such use could be overshad-
owed by several concerns. First, chronic Parib treatment could
induce genomic instability (Curtin and Szabo, 2013). Second,
Paribs would affect not just PARP-1 but also PARP-2, and the
combined reduction of both activities could be detrimental for
long-term viability (Me´nissier de Murcia et al., 2003). Hence,
we characterized the impact of long-term MRL-45696 treatment
in mice. We initially determined that dietary admixture achieved
higher MRL-45696 levels in plasma andmuscle than oral gavage
(Figures S2A and S2B), hence choosing this route for further
studies.
We next fed HFD admixed with MRL-45696 (50 mg/kg/day) to
10-week-old male C57BL/6J mice. MRL-45696 blunted HFD-
induced body weight gain (Figure 1A) due to reduced fat accu-
mulation (Figure 1B) and was associated with higher energyMetabolism 19, 1034–1041, June 3, 2014 ª2014 Elsevier Inc. 1035
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Figure 2. Paribs Enhance Exercise Capacity and Muscle Mitochondrial Function
Chow-fed male C57BL/6J and congenic SIRT1skm/mice (n = 5–10/group) treated with vehicle (DMSO; Veh) and/or MRL-45696 (50mg/kg/day) were subjected
to (A) endurance treadmill test after 13 weeks of treatments, (B) respirometry analysis of permeabilized EDL muscle fibers (CI, complex I; CII, complex II; ETS,
electron transport system), and (C) CS activity measurement. (D) Oleic acid oxidation rate in the muscles of Veh and MRL-45696-treated mice after 18 weeks of
treatment (n = 5–7/group). (E) Mitochondria DNA abundance in quadriceps of Veh and MRL-45696-treated mice (n = 8/group). Results are expressed as
mitochondrial DNA amount (16S) relative to genomic DNA (UCP2). (F) Cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) stainings in gastroc-
nemius of Veh and MRL-45696-treated mice. Soleus is indicated by an arrow. (G) Protein levels of MHCI and IIb were evaluated using heat-shock protein 90
(Hsp90) as a loading control. (H) Myosin heavy chain I staining (MHCI) of gastrocnemius of Veh andMRL-45696-treated mice. Values are shown as mean ± SEM.
Asterisk indicates statistical significant difference versus respective Veh group. *p < 0.05; **p < 0.01; ***p < 0.001. This figure is complemented by Figure S3.
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PARP Inhibitors Improve Muscle Functionexpenditure (Figure 1C), without affecting activity or food intake
(Figures 1D and 1E). Although PARP-1 has been shown to
impact genome stability and cell viability, no evidence for toxicity
on genomic DNA or cellular damage was found, as liver 8-oxo-
dG and muscle lipid peroxidation levels were similar between
the groups (Figures 1F and 1G). This is in line with the fact that
Parp-1/mice are viable and do not show signs of DNAdamage
unless challenged with cytotoxic stimuli (de Murcia et al., 1997).
MRL-45696 reduced total PARP activity in skeletal muscle
(50%; Figure 1H) and in other tissues tested, including brain
and liver (Figure S2C). In line with PARP inhibition, intracellular
NAD+ content was higher in muscle from treatedmice (Figure 1I).
The higher NAD+ levels were restricted to the nuclear and/or
cytosolic compartments, since mitochondrial NAD+ content
was similar between both groups (Figure 1J). Reductions in
PARP activity translated also into SIRT1 activation, as reflected
by lower FOXO1 acetylation, despite slightly lowered SIRT1
levels (Figure 1K). Conversely, the unaltered mitochondrial
NAD+ levels did not change SIRT3 activity, as manifested in1036 Cell Metabolism 19, 1034–1041, June 3, 2014 ª2014 Elsevier Inthe acetylation of NDUFA9 (Figure 1L). These observations are
in line with observations in Parp-1/ mice, where SIRT1, but
not SIRT3, activity was enhanced (Bai et al., 2011).
PARP Inhibition Enhances Endurance andMitochondrial
Function
Given that MRL-45696 accumulates and inhibits PARP in the
skeletal muscle (Figures 1H and S2C), we next examined the
impact of Paribs on muscle performance and mitochondrial
function in chow-fed mice. Despite similar body weight and
composition (Figures S3A–S3C), MRL-45696-treated mice ran
for a significantly longer distance (Figure 2A). Maximal O2 con-
sumption capacity (VO2max), which critically determines endur-
ance performance, was significantly higher with MRL-45696
(Figure S3D). As cardiovascular parameters, including ejection
fraction, fractional shortening, ventricular mass, and diameter
(Figures S3E–S3I), were unchanged, the higher endurance was
most likely due to improved muscle mitochondrial function. To
substantiate this hypothesis, we performed respirometry testsc.
Cell Metabolism
PARP Inhibitors Improve Muscle Functionin permeabilized EDL muscle fibers. Maximal respiration in the
coupled state, with electron input through either complex I
alone—using malate, pyruvate, and glutamate—or complex
I+II—using, in addition, succinate—wasmarkedly higher in mus-
cles after MRL-45696 (Figure 2B). Maximum electron transport
system capacity was also higher after PARP inhibition, even after
the addition of the complex I inhibitor rotenone (Figure 2B).
These results are consistent with the marked increase in citrate
synthase (CS) activity after MRL-45696 (Figure 2C). Finally,
Paribs increased oleic acid oxidation rates by50% (Figure 2D).
Mitochondrial DNA abundance was, however, not changed (Fig-
ure 2E), suggesting that MRL-45696 does not influence muscle
mitochondrial function by increasing mitochondrial number.
Histological analysis further certified that Paribs enhanced the
oxidative profile of skeletal muscle, as testified by more intense
cytochrome c oxidase and succinate dehydrogenase stainings
in gastrocnemius (Figure 2F). Remarkably, an increase in slow
oxidative MHCI, a marker for type 1 fibers, was observed,
whereas MHCIIb levels, a type 2 fiber marker, were decreased
by MRL-45696 (Figure 2G). Furthermore, MHCI staining of
gastrocnemius confirmed the higher type 1 fiber content after
MRL-45696 (Figure 2H). The higher oxidative capacity after
Paribs was accompanied by increased insulin sensitivity, as
reflected by the higher glucose infusion rate during a hyperinsu-
linemic-euglycemic clamp (Figure S3J).
We next evaluated the possible contribution of SIRT1 in
mediating the effects of Paribs by using a muscle-specific
SIRT1-deficient mouse line (SIRT1skm/ mice). In line with pre-
vious reports (Menzies et al., 2013; Philp et al., 2011), endurance
or VO2max was not impaired in SIRT1
skm/ mice (data not
shown). Interestingly, Paribs were unable to enhance endurance,
respiratory capacity, and CS activity in the SIRT1skm/ mice
(Figures 2A–2C). Of note, the expression of Sirt1, Tfam, and
c-mycwas also increased in Parib-treatedmuscles (Figure S3K),
which indicates that a recently identified SIRT1-dependent
pathway (Gomes et al., 2013) by which NAD+ controls metabolic
health might also be at play. Therefore, SIRT1 seems key to the
actions of Paribs on muscle metabolism.
MRL-45696 Enhances Mitochondrial Protein
Translation and Triggers the UPRmt
Paribs increase mitochondrial respiratory capacity in worms by
triggering the mitochondrial unfolded protein response (UPRmt)
in a SIRT1-dependent manner (Mouchiroud et al., 2013). How-
ever, the possible translation of this finding into mammals has
not been explored. We therefore performed blue native PAGE
analyses of mitochondrial complexes in muscles. MRL-45696
increased the abundance of mitochondrial complexes but did
not change their mobility (Figure 3A). Therefore, increased respi-
ratory chain complex content, rather than changes in complex
composition or stoichiometry, accounts for the enhanced mito-
chondrial function. This effect was also observed in cultured
mouse embryonic fibroblasts (MEFs) (Figure S4A). As MRL-
45696 did not affect mRNA levels of mitochondrial complex
subunits (Figure S4B), we speculated that the higher respiratory
complex content could be due to enhanced mitochondrial
protein translation. In line with this hypothesis, MRL-45696 spe-
cifically increased mitochondrial, but not cytosolic (Figures 3B–
3D), protein translation rates in MEFs.CellIncreased mitochondrial translation, without according
changes in cytosolic translation rates, can lead to mitonuclear
protein imbalance (Houtkooper et al., 2013), which was evi-
denced by altered protein ratios between MTCO1, which is
encoded by mtDNA, and SDHA, encoded by nDNA, induced
by MRL-45696 (Figures 3E and 3F). Such a mitonuclear protein
imbalance could trigger UPRmt to restore optimal mitochondrial
function (Houtkooper et al., 2013). In line with this premise, ClpP
and Hsp60 levels, which reflect the presence of UPRmt, were
increased in MRL-45696 treated muscles (Figures 3E and 3F).
Altogether, these results illustrate the robust effects of MRL-
45696 on mitochondrial translation, which culminate in the
induction of UPRmt. While it is not clear how Paribs trigger mito-
nuclear imbalance and UPRmt in mammalian cells, results
obtained in C2C12 cells suggest that SIRT1 is required for
such an effect (Figure S4C), consistent with the mechanisms re-
ported in worms (Mouchiroud et al., 2013). In addition, PARPs
have been reported to silence translation during stress by bind-
ing and/or PARylating RNA-binding proteins that control the
polyadenylation of mRNAs and protein translation rates (for re-
view, see Luo and Kraus, 2012). Hence, the inhibition of PARP
actions on translational processes could be a complementary
mechanism to explain the induction of UPRmt.
Parp-1 Expression Negatively Correlates with Energy
Expenditure
Given the effects of Paribs on mitochondrial function in the
C57BL/6J mouse strain, we next aimed to elucidate whether
Parp-1 could determine energy expenditure and oxidative
capacity in genetically complex mouse populations such as
the BXD mouse genetic population (Peirce et al., 2004).
Parp-1 expression varied 1.3-fold in skeletal muscle of the
BXD strains, enabling the study of gene expression correlations
(Figure 4A). These changes in Parp-1 expression are not related
to natural variations in fiber type composition, as Parp-1 expres-
sion is comparable in muscles having different fiber type
content, such as gastrocnemius or soleus (data not shown).
Parp-1 expression in muscles of the BXDs strains was nega-
tively correlated with night VO2, VO2max improvement after
10 days’ training, and with expression of the troponin I type 1
slow-twitch muscle isoform (Tnni1) (Figure 4B). In contrast,
Parp-1 positively correlated with body weight, troponin C type
2 fast-twitch muscle isoform (Tnnc2) and troponin I type 2
fast-twitch muscle isoform (Tnni2) (Figure 4B). This robust ge-
netic correlation suggests a physiological influence of PARP-1
activity on oxidative metabolism. Indeed, previous results indi-
cated that PARP activity is increased upon HFD (Bai et al.,
2011), likely favoring fat storage over burning (Erener et al.,
2012). Consistent with this, PARP-1 activity was found to
enhance adipogenesis (Erener et al., 2012). Oppositely, PARP
activity was decreased in muscle upon fasting (Bai et al.,
2011), when lipid oxidation is favored. Collectively, this indicates
that physiological changes in PARP-1 activity might help
balancing whole-body energy metabolism
Paribs Improve Oxidative Capacity in Worm and Human
Models of Reduced Mitochondrial Function
To elucidate whether Paribs could recover mitochondrial
function in models with genetically determined mitochondrialMetabolism 19, 1034–1041, June 3, 2014 ª2014 Elsevier Inc. 1037
Figure 3. Paribs Induce UPRmt in Muscle by Increasing Mitochondrial Protein Translation
(A) Blue native PAGE using isolatedmitochondria fromquadriceps of vehicle (DMSO; Veh) andMRL-45696-treatedmice. A nonspecific bandwas used as loading
control. (B) Mitochondrial and (C) cytosolic protein translation measured in MEFs after 100 nM MRL-45696 treatment for 40 hr. (D) Quantification of protein
translation rates. (E) MTCO1, SDHA, ClpP, and Hsp60 protein levels were evaluated in quadriceps from Veh and MRL-45696 mice, using tubulin as a loading
control. (F) Quantification of mitonuclear and UPRmt markers. Values are shown as mean ± SEM. *p < 0.05 and ***p < 0.001. This figure is complemented by
Figure S4.
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PARP Inhibitors Improve Muscle Functiondefects, we first used the C. elegans mev-1 strain, which con-
tains a missense mutation in cyt-1, the worm homolog of
mammalian succinate dehydrogenase cytochrome b, a compo-
nent of complex II (Senoo-Matsuda et al., 2001). The ability of
complex II to catalyze electron transport from succinate to ubi-
quinone is compromised inmev-1mutants, leading to increased
superoxide levels and premature aging. MRL-45696 effectively
inhibited PARP activity (Figure 4C) and increased OCR in mev-
1 mutants (Figure 4D), as previously noticed in wild-type worms
using other Paribs (Mouchiroud et al., 2013). The increased
respiration also translated into effective prevention against
age-related physiological decline, as old mev-1 mutants main-
tained youthful motility (Figure 4E).
To test whether these observations could also apply in human
models, we used skin fibroblasts from a patient with a mutation
in the nuclear NDUFS1 gene, which reduced complex I activity
by 87% (Bugiani et al., 2004). MRL-45696 efficiently prevented
H2O2-induced PARP activation (Figure 4F) and increased NAD
+
(Figure 4G) in NDUFS1 mutant fibroblasts. In line with observa-
tions in mouse tissues, MRL-45696 also increased OCR (Figures
4H–4J), lipid oxidation, and CS activity in these cells, testifying
for enhanced mitochondrial function.1038 Cell Metabolism 19, 1034–1041, June 3, 2014 ª2014 Elsevier InFinally,weevaluatedwhetherParibscould improveacquiredde-
fects in mitochondrial function, such as the decreased mitochon-
drial activity observed in skeletal muscle cells of obese humans
(Patti and Corvera, 2010). MRL-45696 effectively abrogated
PARP activation, enhanced NAD+ levels (Figures 4K and 4L), and
stimulated OCR (Figure 4M) in primary myotubes from obese pa-
tients (Timmers et al., 2012). In addition, MRL-45696 granted a
higher ability to oxidize lipids (Figure 4N), probably by enhancing
mitochondrial function, assuggestedby thehigherCSactivity (Fig-
ure4O).Ourdata therefore illustrate thatParibsenhancemitochon-
drial function in both acquired and genetically determined mito-
chondrial alterations. Hence, the interrelation between PARP
activity and mitochondrial function is well conserved across the
evolutionary spectrum from worms to mice and humans.
Conclusions and Perspectives
In sum, this work provides evidence that drugs used at present in
the cancer field could be retooled to treat metabolic dysfunction
linked to impaired mitochondrial activity, even in a long-term
fashion.Paribsarecurrentlybeing tested for oncology indications,
with positive outcomes in tumors with dysfunctional homologous
DNA recombination repair (Curtin and Szabo, 2013). The successc.
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Figure 4. Parp Activity Negatively Corre-
lates with Energy Expenditure in Mouse
Populations and Its Inhibition Improves
Mitochondrial Function inWorm andHuman
Models of Mitochondria Dysfunction
(A) Expression of Parp-1 in the quadriceps of 37
strains of BXD mice. Each bar represents mRNA
from a pool of approximately five animals per
strain. Extreme strains and the parental strains are
labeled. (B) (Top) Correlation between quadriceps
muscle Parp-1 expression and phenotypes col-
lected from BXD mice. Night VO2 was measured
though indirect calorimetry. VO2 improvement
represents the increase in VO2max after 10 days of
voluntary exercise. (Bottom) Correlation between
quadriceps muscle Parp-1 and muscle fiber type
genes in the same data set. (C) Total PAR content
at day 2 of adulthood (n = 500 worms/sample) in
mev-1(kn1) complex II-deficient C. elegans after
water and 100 nM MRL-45696 treatments. (D)
Respiration at day 3 (n = 10 worms/well, 19 wells/
group) and (E) movement at days 1, 3, and 5 of
adulthood (n = 37–90 worms/group). (F) H2O2
(500 mM)-induced PAR content after 48 hr pre-
treatment with either vehicle (Veh) or 100 nMMRL-
45696 inNDUFS1mutant human fibroblasts. (G–J)
NAD+ levels (G), O2 consumption rates (H), oleic
acid oxidation (I), and CS activity (J) in human
NDUFS1 mutant fibroblasts after Veh and 100 nM
MRL-45696 for 48 hr (n = 3–12 samples/group). (K)
H2O2 (500 mM)-induced PAR content after 24 hr
pretreatment with either Veh or 10 nMMRL-45696
in human primary myotubes. (L–O) NAD+ levels (L),
O2 consumption rates (M), oleic acid oxidation (N),
and CS activity (O) in human primary myotubes
after Veh or 10 nM MRL-45696 treatment for 72 hr
(n = 6–12 samples/group). Asterisk indicates
statistical significant difference versus respective
Veh group. Values are shown as mean ± SEM. *p <
0.05; **p < 0.01; ***p < 0.001.
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PARP Inhibitors Improve Muscle FunctionofParibs is thought to rely on thehighdependencyof thesecancer
cells on PARP enzymes for DNA repair (Curtin and Szabo, 2013),
but could also involve their capacity to reprogram cells toward
oxidativemetabolism (Bai et al., 2011). Notably, Paribs are in gen-
eral well tolerated by patients, with few reported side effects (Au-
deh et al., 2010; Bundred et al., 2013; Tutt et al., 2010). Within the
time frameof this study, and in linewith findings inParp-1/mice
(Bai et al., 2011) and in patients treatedwithOlaparib (Audehet al.,
2010; Bundred et al., 2013; Tutt et al., 2010), no toxicity or
genomic instability was seen in MRL-45696-treated mice. In
contrast, marked metabolic effects were observed, such as
improved mitochondrial function and protection against diet-
induced obesity. Importantly, PARP inhibition rescued mitochon-
drial activity in situations of genetically determined mitochondrialCell Metabolism 19, 1034–10dysfunction. Therefore, our results open
the path of usingParibs to improve invalid-
ating diseases caused by impaired mito-
chondrial function. While this could also
set the stage forParibs to impingeonother
metabolic complex diseases, such as
seen during type 2 diabetes, further workmust be done to ensure the safety and feasibility of these treat-
ments in non-life-threatening diseases.EXPERIMENTAL PROCEDURES
Materials
BSI-201, ABT-888, and AZD-2281 were purchased from Selleck Chemicals
and PJ-34 from Sigma. MRL-45696, kindly provided by Thomas Vogt from
Merck Research Laboratories, is closely related to the potent Parib, niraparib,
or 2-phenyl-2H-indazole-7-carboxamide (Jones et al., 2009). MRL-45696 is a
dual PARP-1/2 inhibitor with IC50 of 0.8 and 0.3 nM, respectively. In contrast, it
displays an IC50 in the micromolar range against PARP-3, vPARP, and
Tankyrase. C2C12 cells were obtained from ATCC. Myoblasts from obese
patients and NDUFS1mutant fibroblasts were provided by Drs. P. Schrauwen
(Timmers et al., 2012) and M. Zeviani (Bugiani et al., 2004).41, June 3, 2014 ª2014 Elsevier Inc. 1039
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Methods for cellular and molecular assays are provided in the Supplemental
Experimental Procedures.
In Vivo and Ex Vivo Studies
To compare administration routes, male C57BL/6J mice were given MRL-
45696 by gavage or food admix at a dose of 50 mg/kg/day for 5 days.
Mice were sacrificed either 6 hr after the last gavage or in the random fed
state, respectively. MRL-45696 concentration in plasma and muscle was
measured by mass spectrometry. For the long-term animal studies,
10-week-old male C57BL/6J mice (Charles River) or SIRT1skm/ mice
were fed pellets containing vehicle and/or PARP inhibitor (50 mg/kg/day)
for 18 weeks. The generation of SIRT1skm/ mice is described in the Sup-
plemental Experimental Procedures. During the experiment, mice were
housed under a 12 hr dark-light cycle and had ad libitum access to water
and food. Clinical tests were carried out according to standard operational
procedures. Mitochondrial function in permeabilized EDL muscle fibers
was evaluated using the Oxygraph-2k respirometer (Oroboros, Austria).
Correlations in the BXD mouse genetic reference population were identified
using the GeneNetwork database (http://www.genenetwork.org). Details are
in the Supplemental Experimental Procedures. All mouse experiments were
performed according to Swiss regulations and approved by the ethical com-
mission of the Canton de Vaud, Switzerland, under licenses 2465 and
2465.1.
C. elegans Studies
Worm strains were cultured at +20C on nematode growth media agar plates
seeded with E. coli strain OP50. Mev-1(kn1) mutant worms were provided by
the Caenorhabditis Genetics Center (University of Minnesota). Protocols
used for western blotting and worm phenotyping are described in the Supple-
mental Experimental Procedures.
Statistical Methods
Statistical analyses were performed with Prism software (GraphPad).
Differences between two groups were analyzed using Student’s t test
(two-tailed), and multiple comparisons were analyzed by ANOVA with a
Bonferroni post hoc test. A p value less than 0.05 was considered significant.
Data are expressed as means ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2014.04.002.
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